# Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

> **NCT02287428** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 56 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Personalized NeoAntigen Peptides
- **DRUG:** Pembrolizumab
- **DRUG:** Temozolomide
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Poly-ICLC

## Key facts

- **NCT ID:** NCT02287428
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11
- **Primary completion:** 2027-02
- **Final completion:** 2028-02
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287428, "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02287428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*